BR112023006989A2 - Anticorpos biespecíficos anti-pd-1/cd40 e usos dos mesmos - Google Patents

Anticorpos biespecíficos anti-pd-1/cd40 e usos dos mesmos

Info

Publication number
BR112023006989A2
BR112023006989A2 BR112023006989A BR112023006989A BR112023006989A2 BR 112023006989 A2 BR112023006989 A2 BR 112023006989A2 BR 112023006989 A BR112023006989 A BR 112023006989A BR 112023006989 A BR112023006989 A BR 112023006989A BR 112023006989 A2 BR112023006989 A2 BR 112023006989A2
Authority
BR
Brazil
Prior art keywords
antigen
bispecific antibodies
antibodies
binding protein
protein constructs
Prior art date
Application number
BR112023006989A
Other languages
English (en)
Portuguese (pt)
Inventor
Baihong Liu
Yi Yang
Yuelei Shen
Original Assignee
Eucure Beijing Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eucure Beijing Biopharma Co Ltd filed Critical Eucure Beijing Biopharma Co Ltd
Publication of BR112023006989A2 publication Critical patent/BR112023006989A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BR112023006989A 2020-10-14 2021-10-13 Anticorpos biespecíficos anti-pd-1/cd40 e usos dos mesmos BR112023006989A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020120918 2020-10-14
CN2021085335 2021-04-02
PCT/CN2021/123438 WO2022078357A1 (en) 2020-10-14 2021-10-13 Anti-pd-1/cd40 bispecific antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BR112023006989A2 true BR112023006989A2 (pt) 2024-01-02

Family

ID=81207517

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023006989A BR112023006989A2 (pt) 2020-10-14 2021-10-13 Anticorpos biespecíficos anti-pd-1/cd40 e usos dos mesmos

Country Status (11)

Country Link
US (1) US20230220082A1 (https=)
EP (1) EP4229096A4 (https=)
JP (1) JP2023545521A (https=)
KR (1) KR20230092932A (https=)
CN (1) CN116390755A (https=)
AU (1) AU2021359495A1 (https=)
BR (1) BR112023006989A2 (https=)
CA (1) CA3197463A1 (https=)
IL (1) IL302042A (https=)
MX (1) MX2023004275A (https=)
WO (1) WO2022078357A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117624372A (zh) * 2022-08-26 2024-03-01 北京天广实生物技术股份有限公司 靶向cd40和pd-l1的抗体及其用途
CN116023495B (zh) * 2022-09-05 2023-10-03 上海百英生物科技股份有限公司 一种抗cd40纳米抗体及其制备方法与应用
KR20250071228A (ko) * 2022-09-20 2025-05-21 커러스 바이오로직스 피티와이 엘티디 고갈된 면역 세포를 구제하는 방법
CN120584137A (zh) * 2023-01-06 2025-09-02 阿帕特夫研究和发展有限公司 双特异性pd-l1和cd40结合分子以及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110114089A (zh) * 2016-11-02 2019-08-09 埃派斯进有限公司 组合中的抗cd40抗体及其使用方法
EP3755716A4 (en) * 2018-02-23 2021-08-04 Eucure (Beijing) Biopharma Co., Ltd ANTI-PD-1 ANTIBODIES AND USES THEREOF
EP3823987A4 (en) * 2018-07-20 2022-03-02 Eucure (Beijing) Biopharma Co., Ltd ANTI-CD40 ANTIBODIES AND USES THEREOF
JP7575100B2 (ja) * 2018-11-13 2024-10-29 ジェイエヌ バイオサイエンシーズ エルエルシー 免疫細胞活性化のための二重特異性抗体
KR20220103957A (ko) * 2019-10-23 2022-07-25 리브젠 바이오파마 홀딩스 리미티드 항-cd40 결합 분자 및 이를 포함하는 이중-특이적 항체

Also Published As

Publication number Publication date
IL302042A (en) 2023-06-01
AU2021359495A1 (en) 2023-04-13
JP2023545521A (ja) 2023-10-30
EP4229096A1 (en) 2023-08-23
CN116390755A (zh) 2023-07-04
US20230220082A1 (en) 2023-07-13
CA3197463A1 (en) 2022-04-21
MX2023004275A (es) 2023-05-02
EP4229096A4 (en) 2024-06-12
WO2022078357A1 (en) 2022-04-21
KR20230092932A (ko) 2023-06-26

Similar Documents

Publication Publication Date Title
BR112023006989A2 (pt) Anticorpos biespecíficos anti-pd-1/cd40 e usos dos mesmos
BR112022018088A2 (pt) Novos anticorpos anti-lilrb4 e produtos derivados
EA201990672A1 (ru) Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
MX2022011659A (es) Proteinas de union a antigeno que se unen a pd-l1.
MX2022014463A (es) Construcciones de union a antigeno para moleculas diana.
CR20200566A (es) Anticuerpos anti-sirpa y metodos de utilización de los mismos
WO2019060750A3 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
BR112019000431A2 (pt) anticorpos contra tim3 e usos dos mesmos
MX2020012567A (es) Anticuerpos anti-ox40 y metodos de uso.
MY197218A (en) Multispecific antigen-binding molecules and uses thereof
ECSP13012525A (es) Anticuerpos contra metaloproteasa-9 de matriz.
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
BR112017009263A2 (pt) anticorpo ou fragmento do mesmo que se liga a uma cd38 humana, anticorpo biespecífico, anticorpo ou fragmento do mesmo que se liga a cd38 humana e de cinomólgos, epítopo sobre a cd38 humana solúvel, composição e imunoconjugado
BR112019000436A2 (pt) anticorpos anti-pd-1, método de produção e método de uso dos mesmos
MX2018007630A (es) Anticuerpos contra la metaloproteinasa de matriz 9.
AR079944A1 (es) Anticuerpo neutralizante de la actividad de un anticoagulante
BR112017022255A2 (pt) anticorpo humanizado ou humano isolado, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir um anticorpo, e composição farmacêutica
BR112021021281A2 (pt) Anticorpo monoclonal que se liga especificamente ao gitr
BR112019007147A2 (pt) anticorpos anti-o1 e usos dos mesmos
BR112022003635A2 (pt) Anticorpo anti-vsig4 ou fragmento de ligação ao antígeno e seu uso
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
EA202092595A1 (ru) Антитела к siglec-7 и способы их применения
BR112022024339A2 (pt) Anticorpos anti cd200r1 e métodos de uso dos mesmos
BR112022009147A2 (pt) Métodos de tratamento do câncer e métodos para aumentar, potencializar ou estimular uma resposta ou função imune
EA201691414A1 (ru) Антитела к матриксной металлопротеиназе 9 и способы их применения